ArticleLeukemia2013
Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies.
Article in Leukemia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.Haematologica · 2017Trial
- Leveraging a disulfidptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma.Frontiers in immunology · 2025Article
- A Comprehensive View on the Impact of Chlorogenic Acids on Colorectal Cancer.Current issues in molecular biology · 2024Review
- Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na).Pharmaceutics · 2023Review
- Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Molecular and cellular therapies · 2015Article
- Phenotypic screening in cancer drug discovery - past, present and future.Nature reviews. Drug discovery · 2014Review
- Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models.Molecular cancer therapeutics · 2014Article
- An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Immunologic research · 2014Review
- Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer.British journal of cancer · 2014Article
- Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo.International journal of radiation oncology, biology, physics · 2014Article
- Oncogene withdrawal engages the immune system to induce sustained cancer regression.Journal for immunotherapy of cancer · 2014Review
- Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.Expert opinion on investigational drugs · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.